AARD vs LLY vs NVO vs PFE

For growth investors, Eli Lilly and Company (LLY) is the stronger pick with 44.

7% revenue growth year-over-year, versus -1. 6% for Pfizer Inc. (PFE). Novo Nordisk A/S (NVO) offers the better valuation at 12. 4x trailing P/E (2. 0x forward), making it the more compelling value choice. Analysts rate Aardvark Therapeutics, Inc. Common Stock (AARD) a "Buy" — based on 8 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

4x versus Eli Lilly and Company at 50. 6x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 0x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus Eli Lilly and Company's 1. 10x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +429.

1%, compared to -74. 6% for Aardvark Therapeutics, Inc. Common Stock (AARD). Over 10 years, the gap is even starker: LLY returned +1522% versus AARD's -74. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 38β versus Aardvark Therapeutics, Inc. Common Stock's 2. 69β — meaning AARD is approximately 612% more volatile than PFE relative to the S&P 500. On balance sheet safety, Aardvark Therapeutics, Inc. Common Stock (AARD) carries a lower debt/equity ratio of 0% versus 160% for Eli Lilly and Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Eli Lilly and Company (LLY) is pulling ahead at 44.

7% versus -1. 6% for Pfizer Inc. (PFE). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -177. 9% for Aardvark Therapeutics, Inc. Common Stock. Over a 3-year CAGR, LLY leads at 31. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus 0. 0% for Aardvark Therapeutics, Inc. Common Stock — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus 0. 0% for AARD. At the gross margin level — before operating expenses — LLY leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus Eli Lilly and Company's 1. 10x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 0x forward P/E versus 31. 7x for Eli Lilly and Company — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AARD: 705. 8% to $29. 33.

In this comparison, PFE (6.

6% yield), NVO (4. 1% yield), LLY (0. 5% yield) pay a dividend. AARD does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

53), 0. 5% yield, +1522% 10Y return). Aardvark Therapeutics, Inc. Common Stock (AARD) carries a higher beta of 2. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LLY: +1522%, AARD: -74. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AARD is a small-cap quality compounder stock; LLY is a mega-cap high-growth stock; NVO is a mid-cap deep-value stock; PFE is a mid-cap income-oriented stock. LLY, NVO, PFE pay a dividend while AARD does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.